# Medifast Inc: financial statements, quarterly MED · NYSE · CIK 910329 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/med.md) · [Financials](/companies/med/financials.md) · [Filings](/companies/med/filings.md) · [Insiders](/companies/med/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/med/financials.md?period=annual). ## Income statement | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [191 d](/filings/0001628280-26-008656.md) | [175](/filings/0001628280-25-020341.md) | [169](/filings/0000910329-25-000016.md) | [140](/filings/0001628280-25-048332.md) | [119 d](/filings/0001628280-26-008656.md) | [116](/filings/0001628280-26-029898.md) | [106](/filings/0001628280-26-051928.md) | [89.4](/filings/0001628280-26-067165.md) | [75.1 d](/filings/0001628280-26-008656.md) | [76.0](/filings/0001628280-26-029898.md) | [76.4](/filings/0001628280-26-051928.md) | [72.0](/filings/0001628280-26-067165.md) | | Cost of revenue | $m | [49.6 d](/filings/0001628280-26-008656.md) | [47.4](/filings/0001628280-25-020341.md) | [45.1](/filings/0000910329-25-000016.md) | [34.5](/filings/0001628280-25-048332.md) | [30.8 d](/filings/0001628280-26-008656.md) | [31.5](/filings/0001628280-26-029898.md) | [28.9](/filings/0001628280-26-051928.md) | [27.3](/filings/0001628280-26-067165.md) | [23.0 d](/filings/0001628280-26-008656.md) | [24.3](/filings/0001628280-26-029898.md) | [23.0](/filings/0001628280-26-051928.md) | [22.0](/filings/0001628280-26-067165.md) | | Gross profit | $m | [141 d](/filings/0001628280-26-008656.md) | [127](/filings/0001628280-25-020341.md) | [123](/filings/0000910329-25-000016.md) | [106](/filings/0001628280-25-048332.md) | [88.2 d](/filings/0001628280-26-008656.md) | [84.2](/filings/0001628280-26-029898.md) | [76.6](/filings/0001628280-26-051928.md) | [62.2](/filings/0001628280-26-067165.md) | [52.1 d](/filings/0001628280-26-008656.md) | [51.8](/filings/0001628280-26-029898.md) | [53.4](/filings/0001628280-26-051928.md) | [50.0](/filings/0001628280-26-067165.md) | | Selling, general and administrative | $m | [133 d](/filings/0001628280-26-008656.md) | [119](/filings/0001628280-25-020341.md) | [131](/filings/0000910329-25-000016.md) | [104](/filings/0001628280-25-048332.md) | [87.5 d](/filings/0001628280-26-008656.md) | [85.5](/filings/0001628280-26-029898.md) | [77.7](/filings/0001628280-26-051928.md) | [66.2](/filings/0001628280-26-067165.md) | [59.9 d](/filings/0001628280-26-008656.md) | [55.1](/filings/0001628280-26-029898.md) | [57.7](/filings/0001628280-26-051928.md) | [69.4](/filings/0001628280-26-067165.md) | | Operating income | $m | [8.7 d](/filings/0001628280-26-008656.md) | [7.9](/filings/0001628280-25-020341.md) | [(7.9)](/filings/0000910329-25-000016.md) | [2.1](/filings/0001628280-25-048332.md) | [0.7 d](/filings/0001628280-26-008656.md) | [(1.3)](/filings/0001628280-26-029898.md) | [(1.1)](/filings/0001628280-26-051928.md) | [(4.1)](/filings/0001628280-26-067165.md) | [(7.8) d](/filings/0001628280-26-008656.md) | [(3.3)](/filings/0001628280-26-029898.md) | [(4.3)](/filings/0001628280-26-051928.md) | [(19.4)](/filings/0001628280-26-067165.md) | | Income tax | $m | [3.8 d](/filings/0001628280-26-008656.md) | [3.3](/filings/0001628280-25-020341.md) | [(2.5)](/filings/0000910329-25-000016.md) | [0.4](/filings/0001628280-25-048332.md) | [0.5 d](/filings/0001628280-26-008656.md) | [1.3](/filings/0001628280-26-029898.md) | [0.4](/filings/0001628280-26-051928.md) | [(0.4)](/filings/0001628280-26-067165.md) | [11.7 d](/filings/0001628280-26-008656.md) | [0.2](/filings/0001628280-26-029898.md) | [0.1](/filings/0001628280-26-051928.md) | [(0.3)](/filings/0001628280-26-067165.md) | | Net income | $m | [6.0 d](/filings/0001628280-26-008656.md) | [8.3](/filings/0001628280-25-048332.md) | [(8.2)](/filings/0001628280-25-048332.md) | [1.1](/filings/0001628280-25-048332.md) | [0.8 d](/filings/0001628280-26-008656.md) | [(0.8)](/filings/0001628280-26-067165.md) | [2.5](/filings/0001628280-26-067165.md) | [(2.3)](/filings/0001628280-26-067165.md) | [(18.1) d](/filings/0001628280-26-008656.md) | [(2.1)](/filings/0001628280-26-067165.md) | [(3.1)](/filings/0001628280-26-067165.md) | [(17.5)](/filings/0001628280-26-067165.md) | | Diluted EPS | $ per share | not reported | [0.76](/filings/0001628280-25-020341.md) | [(0.75)](/filings/0000910329-25-000016.md) | [0.10](/filings/0001628280-25-048332.md) | not reported | [(0.07)](/filings/0001628280-26-029898.md) | [0.22](/filings/0001628280-26-051928.md) | [(0.21)](/filings/0001628280-26-067165.md) | not reported | [(0.19)](/filings/0001628280-26-029898.md) | [(0.28)](/filings/0001628280-26-051928.md) | [(1.57)](/filings/0001628280-26-067165.md) | | Basic EPS | $ per share | not reported | [0.76](/filings/0001628280-25-020341.md) | [(0.75)](/filings/0000910329-25-000016.md) | [0.10](/filings/0001628280-25-048332.md) | not reported | [(0.07)](/filings/0001628280-26-029898.md) | [0.23](/filings/0001628280-26-051928.md) | [(0.21)](/filings/0001628280-26-067165.md) | not reported | [(0.19)](/filings/0001628280-26-029898.md) | [(0.28)](/filings/0001628280-26-051928.md) | [(1.57)](/filings/0001628280-26-067165.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [94.4](/filings/0001628280-25-006094.md) | [97.5](/filings/0001628280-24-019046.md) | [108](/filings/0001628280-24-034791.md) | [115](/filings/0001628280-24-045040.md) | [90.9](/filings/0001628280-26-008656.md) | [91.7](/filings/0001628280-25-020341.md) | [102](/filings/0000910329-25-000016.md) | [99.5](/filings/0001628280-25-048332.md) | [89.3](/filings/0001628280-26-067165.md) | [71.5](/filings/0001628280-26-029898.md) | [71.9](/filings/0001628280-26-051928.md) | [58.4](/filings/0001628280-26-067165.md) | | Current assets | $m | [224](/filings/0001628280-25-006094.md) | [220](/filings/0001628280-24-019046.md) | [224](/filings/0001628280-24-034791.md) | [225](/filings/0001628280-24-045040.md) | [214](/filings/0001628280-26-008656.md) | [214](/filings/0001628280-25-020341.md) | [206](/filings/0000910329-25-000016.md) | [208](/filings/0001628280-25-048332.md) | [202](/filings/0001628280-26-067165.md) | [203](/filings/0001628280-26-029898.md) | [202](/filings/0001628280-26-051928.md) | [202](/filings/0001628280-26-067165.md) | | Total assets | $m | [310](/filings/0001628280-25-006094.md) | [303](/filings/0001628280-24-019046.md) | [294](/filings/0001628280-24-034791.md) | [291](/filings/0001628280-24-045040.md) | [284](/filings/0001628280-26-008656.md) | [280](/filings/0001628280-25-020341.md) | [269](/filings/0000910329-25-000016.md) | [268](/filings/0001628280-25-048332.md) | [248](/filings/0001628280-26-067165.md) | [252](/filings/0001628280-26-029898.md) | [260](/filings/0001628280-26-051928.md) | [240](/filings/0001628280-26-067165.md) | | Current liabilities | $m | [92.3](/filings/0001628280-25-006094.md) | [77.2](/filings/0001628280-24-019046.md) | [75.2](/filings/0001628280-24-034791.md) | [72.4](/filings/0001628280-24-045040.md) | [64.2](/filings/0001628280-26-008656.md) | [60.6](/filings/0001628280-25-020341.md) | [46.2](/filings/0000910329-25-000016.md) | [46.7](/filings/0001628280-25-048332.md) | [43.0](/filings/0001628280-26-067165.md) | [42.2](/filings/0001628280-26-029898.md) | [41.6](/filings/0001628280-26-051928.md) | [41.9](/filings/0001628280-26-067165.md) | | Total liabilities | $m | [108](/filings/0001628280-25-006094.md) | [91.8](/filings/0001628280-24-019046.md) | [88.2](/filings/0001628280-24-034791.md) | [83.9](/filings/0001628280-24-045040.md) | [74.1](/filings/0001628280-26-008656.md) | [69.1](/filings/0001628280-25-020341.md) | [53.3](/filings/0000910329-25-000016.md) | [53.5](/filings/0001628280-25-048332.md) | [49.1](/filings/0001628280-26-067165.md) | [54.4](/filings/0001628280-26-029898.md) | [64.0](/filings/0001628280-26-051928.md) | [59.5](/filings/0001628280-26-067165.md) | | Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [201](/filings/0001628280-26-008656.md) | [211](/filings/0001628280-25-048332.md) | [205](/filings/0001628280-25-048332.md) | [207](/filings/0001628280-25-048332.md) | [210](/filings/0001628280-26-067165.md) | [211](/filings/0001628280-26-067165.md) | [216](/filings/0001628280-26-067165.md) | [215](/filings/0001628280-26-067165.md) | [199](/filings/0001628280-26-067165.md) | [198](/filings/0001628280-26-067165.md) | [196](/filings/0001628280-26-067165.md) | [180](/filings/0001628280-26-067165.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: not reported - Current portion of debt: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [10.5 d](/filings/0001628280-26-008656.md) | [7.3](/filings/0001628280-25-020341.md) | [13.1 d](/filings/0000910329-25-000016.md) | [9.1 d](/filings/0001628280-25-048332.md) | [(4.9) d](/filings/0001628280-26-008656.md) | [3.4](/filings/0001628280-26-029898.md) | [(3.4) d](/filings/0001628280-26-051928.md) | [12.1 d](/filings/0001628280-26-067165.md) | [(5.3) d](/filings/0001628280-26-008656.md) | [0.3](/filings/0001628280-26-029898.md) | [1.7 d](/filings/0001628280-26-051928.md) | [3.3 d](/filings/0001628280-26-067165.md) | | Capital expenditure | $m | [0.9 d](/filings/0001628280-26-008656.md) | [1.8](/filings/0001628280-25-020341.md) | [1.9 d](/filings/0000910329-25-000016.md) | [1.4 d](/filings/0001628280-25-048332.md) | [2.3 d](/filings/0001628280-26-008656.md) | [1.5](/filings/0001628280-26-029898.md) | [1.4 d](/filings/0001628280-26-051928.md) | [1.4 d](/filings/0001628280-26-067165.md) | [1.4 d](/filings/0001628280-26-008656.md) | [1.1](/filings/0001628280-26-029898.md) | [1.0 d](/filings/0001628280-26-051928.md) | [0.4 d](/filings/0001628280-26-067165.md) | | Dividends paid | $m | [18.0 d](/filings/0001628280-26-008656.md) | [0.7](/filings/0001628280-25-020341.md) | [0.0 d](/filings/0000910329-25-000016.md) | [0.0 d](/filings/0001628280-25-048332.md) | [0.0 d](/filings/0001628280-26-008656.md) | [0.2](/filings/0001628280-26-029898.md) | [0.0 d](/filings/0001628280-26-051928.md) | [0.0 d](/filings/0001628280-26-067165.md) | [0.0 d](/filings/0001628280-26-008656.md) | [0.1](/filings/0001628280-26-029898.md) | [0.1 d](/filings/0001628280-26-051928.md) | [0.0 d](/filings/0001628280-26-067165.md) | | Share repurchases | $m | [0.0 d](/filings/0001628280-26-008656.md) | [0.0](/filings/0001628280-24-019046.md) | [0.0 d](/filings/0001628280-24-034791.md) | [0.0 d](/filings/0001628280-24-045040.md) | [0.0 d](/filings/0001628280-26-008656.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividends - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [10.9](/filings/0001628280-24-019046.md) | [10.9](/filings/0001628280-24-034791.md) | [10.9](/filings/0001628280-24-045040.md) | [11.0](/filings/0001628280-25-020341.md) | [10.9](/filings/0000910329-25-000016.md) | [11.0](/filings/0001628280-25-048332.md) | [10.9](/filings/0001628280-26-029898.md) | [11.1](/filings/0001628280-26-051928.md) | [11.0](/filings/0001628280-26-067165.md) | [11.0](/filings/0001628280-26-029898.md) | [11.1](/filings/0001628280-26-051928.md) | [11.2](/filings/0001628280-26-067165.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 11,182,597 at 2026-10-19, from the cover of the [10-Q filed 2026-10-26](/filings/0001628280-26-067165.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 31, 2026, 14:35 ET. No prices; not investment advice.